China: These 50 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027
DrugPatentWatch® Estimated Loss of Exclusivity Dates in China
Generic Entry Dates in Other Countries
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
Summary: China: These 50 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027
| Tradename | Ingredient | Estimated Entry Opportunity Date |
|---|---|---|
| QVAR REDIHALER | beclomethasone dipropionate | 2027-04-11 |
| CREON | pancrelipase (amylase;lipase;protease) | 2026-08-15 |
| PANCREAZE | pancrelipase (amylase;lipase;protease) | 2027-02-20 |
| ZENPEP | pancrelipase (amylase;lipase;protease) | 2027-02-20 |
| EMBEDA | morphine sulfate; naltrexone hydrochloride | 2027-06-19 |
| >Tradename | >Ingredient | >Estimated Entry Opportunity Date |
Details: China: These 50 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027
When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch?
Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 11, 2027
Generic Entry Controlled by: China Patent 101,657,829
This drug has two hundred and seventy-eight patent family members in twenty-seven countries. There has been litigation on patents covering QVAR REDIHALER
See drug price trends for QVAR REDIHALER.
The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2026
Generic Entry Controlled by: China Patent 101,242,811
CREON is a drug marketed by
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2026
Generic Entry Controlled by: China Patent 101,242,812
CREON is a drug marketed by
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 20, 2027
Generic Entry Controlled by: China Patent 101,686,943
PANCREAZE is a drug marketed by
See drug price trends for PANCREAZE.
The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 20, 2027
Generic Entry Controlled by: China Patent 101,686,943
ZENPEP is a drug marketed by
See drug price trends for ZENPEP.
The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch?
Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: China Patent 101,677,963
EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.
This drug has seventy-four patent family members in twenty-three countries.
See drug price trends for EMBEDA.
The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.
When can FARYDAK (panobinostat lactate) generic drug versions launch?
Generic name: panobinostat lactate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 12, 2026
Generic Entry Controlled by: China Patent 101,641,328
FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.
This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK
See drug price trends for FARYDAK.
The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.
When can FARYDAK (panobinostat lactate) generic drug versions launch?
Generic name: panobinostat lactate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 12, 2026
Generic Entry Controlled by: China Patent 102,584,673
FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.
This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK
See drug price trends for FARYDAK.
The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.
When can LYNPARZA (olaparib) generic drug versions launch?
Generic name: olaparib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 15, 2027
Generic Entry Controlled by: China Patent 101,528,714
LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.
This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA
See drug price trends for LYNPARZA.
The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.
When can LYNPARZA (olaparib) generic drug versions launch?
Generic name: olaparib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 17, 2026
Generic Entry Controlled by: China Patent 104,649,979
LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.
This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA
See drug price trends for LYNPARZA.
The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.
When can NINLARO (ixazomib citrate) generic drug versions launch?
Generic name: ixazomib citrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 06, 2027
Generic Entry Controlled by: China Patent 101,772,507
NINLARO is a drug marketed by Takeda Pharms Usa. There are seven patents protecting this drug.
This drug has one hundred and eighty-seven patent family members in forty-four countries. There has been litigation on patents covering NINLARO
See drug price trends for NINLARO.
The generic ingredient in NINLARO is ixazomib citrate. One supplier is listed for this generic product. Additional details are available on the ixazomib citrate profile page.
When can NINLARO (ixazomib citrate) generic drug versions launch?
Generic name: ixazomib citrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 06, 2027
Generic Entry Controlled by: China Patent 102,961,387
NINLARO is a drug marketed by Takeda Pharms Usa. There are seven patents protecting this drug.
This drug has one hundred and eighty-seven patent family members in forty-four countries. There has been litigation on patents covering NINLARO
See drug price trends for NINLARO.
The generic ingredient in NINLARO is ixazomib citrate. One supplier is listed for this generic product. Additional details are available on the ixazomib citrate profile page.
When can NINLARO (ixazomib citrate) generic drug versions launch?
Generic name: ixazomib citrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 06, 2027
Generic Entry Controlled by: China Patent 105,837,608
NINLARO is a drug marketed by Takeda Pharms Usa. There are seven patents protecting this drug.
This drug has one hundred and eighty-seven patent family members in forty-four countries. There has been litigation on patents covering NINLARO
See drug price trends for NINLARO.
The generic ingredient in NINLARO is ixazomib citrate. One supplier is listed for this generic product. Additional details are available on the ixazomib citrate profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 28, 2026
Generic Entry Controlled by: China Patent 102,627,639
OLYSIO is a drug marketed by Janssen Prods. There are eight patents protecting this drug.
This drug has sixty-four patent family members in forty-one countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can XALKORI (crizotinib) generic drug versions launch?
Generic name: crizotinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 23, 2026
Generic Entry Controlled by: China Patent 101,326,175
XALKORI is a drug marketed by Pf Prism Cv. There are three patents protecting this drug.
This drug has one hundred and five patent family members in forty-six countries.
See drug price trends for XALKORI.
The generic ingredient in XALKORI is crizotinib. One supplier is listed for this generic product. Additional details are available on the crizotinib profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: China Patent 101,479,287
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: China Patent 103,145,773
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: China Patent 101,541,320
This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO
See drug price trends for EPIDUO.
The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: China Patent 101,541,320
See drug price trends for EPIDUO FORTE.
The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can VIZAMYL (flutemetamol f-18) generic drug versions launch?
Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 30, 2027
Generic Entry Controlled by: China Patent 101,790,387
VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.
This drug has twenty-three patent family members in twenty countries.
See drug price trends for VIZAMYL.
The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this generic product. Additional details are available on the flutemetamol f-18 profile page.
When can SALONPAS (menthol; methyl salicylate) generic drug versions launch?
Generic name: menthol; methyl salicylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 04, 2026
Generic Entry Controlled by: China Patent 101,442,993
SALONPAS is a drug marketed by Hisamitsu Pharm Co. There are two patents protecting this drug.
This drug has twenty patent family members in sixteen countries.
The generic ingredient in SALONPAS is menthol; methyl salicylate. There are eighteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the menthol; methyl salicylate profile page.
When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?
Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 24, 2027
Generic Entry Controlled by: China Patent 101,677,965
SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.
See drug price trends for SIGNIFOR LAR.
The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.
When can LASTACAFT (alcaftadine) generic drug versions launch?
Generic name: alcaftadine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 31, 2026
Generic Entry Controlled by: China Patent 101,460,176
This drug has forty-six patent family members in thirty countries. There has been litigation on patents covering LASTACAFT
See drug price trends for LASTACAFT.
The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the alcaftadine profile page.
When can AMYVID (florbetapir f-18) generic drug versions launch?
Generic name: florbetapir f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2026
Generic Entry Controlled by: China Patent 101,522,624
AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.
This drug has fifty-one patent family members in thirty-three countries. There has been litigation on patents covering AMYVID
The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: China Patent 106,083,969
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.
When can DYANAVEL XR (amphetamine) generic drug versions launch?
Generic name: amphetamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 15, 2027
Generic Entry Controlled by: China Patent 101,400,343
This drug has twenty-one patent family members in fourteen countries. There has been litigation on patents covering DYANAVEL XR
See drug price trends for DYANAVEL XR.
The generic ingredient in DYANAVEL XR is amphetamine. There are fifty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the amphetamine profile page.
When can DYANAVEL XR (amphetamine) generic drug versions launch?
Generic name: amphetamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 15, 2027
Generic Entry Controlled by: China Patent 102,488,652
This drug has twenty-one patent family members in fourteen countries. There has been litigation on patents covering DYANAVEL XR
See drug price trends for DYANAVEL XR.
The generic ingredient in DYANAVEL XR is amphetamine. There are fifty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the amphetamine profile page.
When can INVOKAMET XR (canagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 04, 2026
Generic Entry Controlled by: China Patent 101,573,368
This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKAMET XR
See drug price trends for INVOKAMET XR.
The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.
When can ORENITRAM (treprostinil diolamine) generic drug versions launch?
Generic name: treprostinil diolamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 27, 2026
Generic Entry Controlled by: China Patent 101,466,384
ORENITRAM is a drug marketed by United Therap. There are nine patents protecting this drug and two Paragraph IV challenges.
This drug has fifty-nine patent family members in eight countries. There has been litigation on patents covering ORENITRAM
See drug price trends for ORENITRAM.
The generic ingredient in ORENITRAM is treprostinil diolamine. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the treprostinil diolamine profile page.
When can BELSOMRA (suvorexant) generic drug versions launch?
Generic name: suvorexant
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 30, 2027
Generic Entry Controlled by: China Patent 101,627,028
This drug has seventy-five patent family members in thirty-six countries.
See drug price trends for BELSOMRA.
The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this generic product. Additional details are available on the suvorexant profile page.
When can BELSOMRA (suvorexant) generic drug versions launch?
Generic name: suvorexant
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 01, 2026
Generic Entry Controlled by: China Patent 101,880,276
This drug has seventy-five patent family members in thirty-six countries.
See drug price trends for BELSOMRA.
The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this generic product. Additional details are available on the suvorexant profile page.
When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch?
Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 08, 2027
Generic Entry Controlled by: China Patent 101,778,840
This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA
See drug price trends for DAKLINZA.
The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.
When can EDARBI (azilsartan kamedoxomil) generic drug versions launch?
Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 28, 2027
Generic Entry Controlled by: China Patent 101,677,961
This drug has twenty-one patent family members in seventeen countries. There has been litigation on patents covering EDARBI
See drug price trends for EDARBI.
The generic ingredient in EDARBI is azilsartan kamedoxomil. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the azilsartan kamedoxomil profile page.
When can EXFORGE HCT (amlodipine besylate; hydrochlorothiazide; valsartan) generic drug versions launch?
Generic name: amlodipine besylate; hydrochlorothiazide; valsartan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 27, 2026
Generic Entry Controlled by: China Patent 101,478,956
See drug price trends for EXFORGE HCT.
The generic ingredient in EXFORGE HCT is amlodipine besylate; hydrochlorothiazide; valsartan. There are fifty drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the amlodipine besylate; hydrochlorothiazide; valsartan profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: China Patent 101,479,287
This drug has four hundred and twenty-three patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: China Patent 103,145,773
This drug has four hundred and twenty-three patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can INLYTA (axitinib) generic drug versions launch?
Generic name: axitinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 05, 2027
Generic Entry Controlled by: China Patent 103,626,739
INLYTA is a drug marketed by Pf Prism Cv. There are three patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has ninety-seven patent family members in thirty countries. There has been litigation on patents covering INLYTA
See drug price trends for INLYTA.
The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the axitinib profile page.
When can INVOKAMET (canagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 04, 2026
Generic Entry Controlled by: China Patent 101,573,368
This drug has two hundred and seventy-one patent family members in forty-eight countries. There has been litigation on patents covering INVOKAMET
See drug price trends for INVOKAMET.
The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: China Patent 101,932,582
JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: China Patent 103,524,509
JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can JYNARQUE (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 01, 2026
Generic Entry Controlled by: China Patent 101,273,017
JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE
See drug price trends for JYNARQUE.
The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch?
Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 19, 2027
Generic Entry Controlled by: China Patent 101,801,351
This drug has ninety patent family members in forty-one countries. There has been litigation on patents covering KAZANO
See drug price trends for KAZANO.
The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. There are ten drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.
When can OPSUMIT (macitentan) generic drug versions launch?
Generic name: macitentan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 29, 2026
Generic Entry Controlled by: China Patent 101,511,365
OPSUMIT is a drug marketed by Actelion. There are five patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred patent family members in thirty-five countries. There has been litigation on patents covering OPSUMIT
See drug price trends for OPSUMIT.
The generic ingredient in OPSUMIT is macitentan. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the macitentan profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: China Patent 101,479,287
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: China Patent 103,145,773
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can SAMSCA (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 01, 2026
Generic Entry Controlled by: China Patent 101,273,017
SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA
See drug price trends for SAMSCA.
The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can SAVAYSA (edoxaban tosylate) generic drug versions launch?
Generic name: edoxaban tosylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 29, 2027
Generic Entry Controlled by: China Patent 104,324,015
This drug has one hundred and one patent family members in thirty-four countries. There has been litigation on patents covering SAVAYSA
See drug price trends for SAVAYSA.
The generic ingredient in SAVAYSA is edoxaban tosylate. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the edoxaban tosylate profile page.
When can TRADJENTA (linagliptin) generic drug versions launch?
Generic name: linagliptin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 04, 2026
Generic Entry Controlled by: China Patent 101,437,493
This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA
See drug price trends for TRADJENTA.
The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.
When can TRADJENTA (linagliptin) generic drug versions launch?
Generic name: linagliptin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 04, 2026
Generic Entry Controlled by: China Patent 102,526,737
This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA
See drug price trends for TRADJENTA.
The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.
When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch?
Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 16, 2026
Generic Entry Controlled by: China Patent 101,472,906
This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX
See drug price trends for TRINTELLIX.
The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.
When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch?
Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 15, 2027
Generic Entry Controlled by: China Patent 102,614,179
This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX
See drug price trends for TRINTELLIX.
The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.
When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch?
Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 16, 2026
Generic Entry Controlled by: China Patent 102,617,513
This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX
See drug price trends for TRINTELLIX.
The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.
When can XADAGO (safinamide mesylate) generic drug versions launch?
Generic name: safinamide mesylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 08, 2027
Generic Entry Controlled by: China Patent 101,472,880
This drug has ninety-seven patent family members in thirty-one countries. There has been litigation on patents covering XADAGO
See drug price trends for XADAGO.
The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the safinamide mesylate profile page.
When can XADAGO (safinamide mesylate) generic drug versions launch?
Generic name: safinamide mesylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: China Patent 103,284,984
This drug has ninety-seven patent family members in thirty-one countries. There has been litigation on patents covering XADAGO
See drug price trends for XADAGO.
The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the safinamide mesylate profile page.
When can ZEMDRI (plazomicin sulfate) generic drug versions launch?
Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 21, 2027
Generic Entry Controlled by: China Patent 101,868,472
ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug.
This drug has twenty-eight patent family members in twenty-one countries. There has been litigation on patents covering ZEMDRI
See drug price trends for ZEMDRI.
The generic ingredient in ZEMDRI is plazomicin sulfate. Three suppliers are listed for this generic product. Additional details are available on the plazomicin sulfate profile page.
When can ZEMDRI (plazomicin sulfate) generic drug versions launch?
Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 21, 2027
Generic Entry Controlled by: China Patent 103,360,440
ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug.
This drug has twenty-eight patent family members in twenty-one countries. There has been litigation on patents covering ZEMDRI
See drug price trends for ZEMDRI.
The generic ingredient in ZEMDRI is plazomicin sulfate. Three suppliers are listed for this generic product. Additional details are available on the plazomicin sulfate profile page.
When can XENLETA (lefamulin acetate) generic drug versions launch?
Generic name: lefamulin acetate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 20, 2027
Generic Entry Controlled by: China Patent 101,668,738
XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.
This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA
See drug price trends for XENLETA.
The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.
When can XENLETA (lefamulin acetate) generic drug versions launch?
Generic name: lefamulin acetate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 20, 2027
Generic Entry Controlled by: China Patent 104,211,624
XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.
This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA
See drug price trends for XENLETA.
The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.
When can BYFAVO (remimazolam besylate) generic drug versions launch?
Generic name: remimazolam besylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2027
Generic Entry Controlled by: China Patent 101,501,019
BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug.
This drug has fifty-three patent family members in twenty-four countries. There has been litigation on patents covering BYFAVO
See drug price trends for BYFAVO.
The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this generic product. Additional details are available on the remimazolam besylate profile page.
When can BYFAVO (remimazolam besylate) generic drug versions launch?
Generic name: remimazolam besylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2027
Generic Entry Controlled by: China Patent 103,288,834
BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug.
This drug has fifty-three patent family members in twenty-four countries. There has been litigation on patents covering BYFAVO
See drug price trends for BYFAVO.
The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this generic product. Additional details are available on the remimazolam besylate profile page.
When can BYFAVO (remimazolam besylate) generic drug versions launch?
Generic name: remimazolam besylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2027
Generic Entry Controlled by: China Patent 104,059,071
BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug.
This drug has fifty-three patent family members in twenty-four countries. There has been litigation on patents covering BYFAVO
See drug price trends for BYFAVO.
The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this generic product. Additional details are available on the remimazolam besylate profile page.
When can BYFAVO (remimazolam besylate) generic drug versions launch?
Generic name: remimazolam besylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2027
Generic Entry Controlled by: China Patent 104,059,072
BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug.
This drug has fifty-three patent family members in twenty-four countries. There has been litigation on patents covering BYFAVO
See drug price trends for BYFAVO.
The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this generic product. Additional details are available on the remimazolam besylate profile page.
When can INQOVI (cedazuridine; decitabine) generic drug versions launch?
Generic name: cedazuridine; decitabine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 16, 2027
Generic Entry Controlled by: China Patent 101,827,856
INQOVI is a drug marketed by Taiho Oncology. There are six patents protecting this drug.
This drug has ninety-three patent family members in forty-one countries. There has been litigation on patents covering INQOVI
See drug price trends for INQOVI.
The generic ingredient in INQOVI is cedazuridine; decitabine. One supplier is listed for this generic product. Additional details are available on the cedazuridine; decitabine profile page.
When can TRELSTAR (triptorelin pamoate) generic drug versions launch?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 06, 2027
Generic Entry Controlled by: China Patent 101,677,959
TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.
This drug has forty-seven patent family members in thirty-two countries.
See drug price trends for TRELSTAR.
The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.
When can WINLEVI (clascoterone) generic drug versions launch?
Generic name: clascoterone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 03, 2027
Generic Entry Controlled by: China Patent 103,450,304
This drug has ninety-three patent family members in twenty-nine countries. There has been litigation on patents covering WINLEVI
See drug price trends for WINLEVI.
The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.
When can WINLEVI (clascoterone) generic drug versions launch?
Generic name: clascoterone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 03, 2027
Generic Entry Controlled by: China Patent 104,861,023
This drug has ninety-three patent family members in twenty-nine countries. There has been litigation on patents covering WINLEVI
See drug price trends for WINLEVI.
The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.
When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch?
Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: China Patent 101,687,857
TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.
This drug has seventy-nine patent family members in thirty-six countries. There has been litigation on patents covering TEPMETKO
See drug price trends for TEPMETKO.
The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.
When can KERENDIA (finerenone) generic drug versions launch?
Generic name: finerenone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 27, 2027
Generic Entry Controlled by: China Patent 101,641,352
This drug has ninety-seven patent family members in forty-nine countries. There has been litigation on patents covering KERENDIA
See drug price trends for KERENDIA.
The generic ingredient in KERENDIA is finerenone. One supplier is listed for this generic product. Additional details are available on the finerenone profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 10, 2026
Generic Entry Controlled by: China Patent 101,535,336
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.
This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 10, 2026
Generic Entry Controlled by: China Patent 101,627,049
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.
This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.
When can OPZELURA (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: China Patent 101,932,582
This drug has three hundred and thirty-seven patent family members in forty-nine countries. There has been litigation on patents covering OPZELURA
See drug price trends for OPZELURA.
The generic ingredient in OPZELURA is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can OPZELURA (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: China Patent 103,524,509
This drug has three hundred and thirty-seven patent family members in forty-nine countries. There has been litigation on patents covering OPZELURA
See drug price trends for OPZELURA.
The generic ingredient in OPZELURA is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can INVOKAMET XR (canagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 04, 2026
Generic Entry Controlled by: China Patent 102,675,299
This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKAMET XR
See drug price trends for INVOKAMET XR.
The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.
When can INVOKAMET XR (canagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2027
Generic Entry Controlled by: China Patent 102,675,380
This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKAMET XR
See drug price trends for INVOKAMET XR.
The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.
When can INVOKAMET (canagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 04, 2026
Generic Entry Controlled by: China Patent 102,675,299
This drug has two hundred and seventy-one patent family members in forty-eight countries. There has been litigation on patents covering INVOKAMET
See drug price trends for INVOKAMET.
The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.
When can INVOKAMET (canagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2027
Generic Entry Controlled by: China Patent 102,675,380
This drug has two hundred and seventy-one patent family members in forty-eight countries. There has been litigation on patents covering INVOKAMET
See drug price trends for INVOKAMET.
The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2026
Generic Entry Controlled by: China Patent 101,267,810
ESBRIET is a drug marketed by Legacy Pharma. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2026
Generic Entry Controlled by: China Patent 103,393,607
ESBRIET is a drug marketed by Legacy Pharma. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2026
Generic Entry Controlled by: China Patent 103,735,530
ESBRIET is a drug marketed by Legacy Pharma. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can LEXISCAN (regadenoson) generic drug versions launch?
Generic name: regadenoson
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 02, 2027
Generic Entry Controlled by: China Patent 101,379,073
LEXISCAN is a drug marketed by Astellas. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-eight patent family members in eighteen countries. There has been litigation on patents covering LEXISCAN
See drug price trends for LEXISCAN.
The generic ingredient in LEXISCAN is regadenoson. There are nine drug master file entries for this API. Seventeen suppliers are listed for this generic product. Additional details are available on the regadenoson profile page.
When can LYNPARZA (olaparib) generic drug versions launch?
Generic name: olaparib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 17, 2026
Generic Entry Controlled by: China Patent 102,627,611
LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.
This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA
See drug price trends for LYNPARZA.
The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: China Patent 106,146,594
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.
When can RYTARY (carbidopa; levodopa) generic drug versions launch?
Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 28, 2027
Generic Entry Controlled by: China Patent 101,910,113
RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges.
This drug has twenty-five patent family members in twelve countries. There has been litigation on patents covering RYTARY
See drug price trends for RYTARY.
The generic ingredient in RYTARY is carbidopa; levodopa. There are eighteen drug master file entries for this API. Thirty-seven suppliers are listed for this generic product. Additional details are available on the carbidopa; levodopa profile page.